Goldman Sachs Group Inc Intellia Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,034,481 shares of NTLA stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,034,481
Previous 1,266,602 18.33%
Holding current value
$13.8 Million
Previous $28.3 Million 25.01%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$19.72 - $27.36 $4.58 Million - $6.35 Million
-232,121 Reduced 18.33%
1,034,481 $21.3 Million
Q2 2024

Aug 13, 2024
BUY
$20.02 - $27.22 $3.99 Million - $5.42 Million
199,142 Added 18.66%
1,266,602 $28.3 Million
Q1 2024

May 15, 2024
BUY
$23.82 - $32.8 $5.79 Million - $7.97 Million
242,933 Added 29.46%
1,067,460 $29.4 Million
Q4 2023

Feb 13, 2024
BUY
$23.16 - $32.34 $654,594 - $914,057
28,264 Added 3.55%
824,527 $25.1 Million
Q3 2023

May 14, 2024
SELL
$31.62 - $45.78 $893,707 - $1.29 Million
-28,264 Reduced 3.43%
796,263 $25.2 Million
Q3 2023

Nov 14, 2023
SELL
$31.62 - $45.78 $6.56 Million - $9.5 Million
-207,503 Reduced 20.67%
796,263 $25.2 Million
Q2 2023

May 14, 2024
BUY
$34.58 - $46.03 $4.99 Million - $6.64 Million
144,284 Added 16.79%
1,003,766 $40.9 Million
Q2 2023

Aug 14, 2023
BUY
$34.58 - $46.03 $4.99 Million - $6.64 Million
144,284 Added 16.79%
1,003,766 $40.9 Million
Q1 2023

May 14, 2024
BUY
$33.3 - $44.82 $7.74 Million - $10.4 Million
232,388 Added 37.06%
859,482 $32 Million
Q1 2023

May 11, 2023
BUY
$33.3 - $44.82 $7.74 Million - $10.4 Million
232,388 Added 37.06%
859,482 $32 Million
Q4 2022

May 14, 2024
SELL
$33.21 - $62.69 $11.8 Million - $22.2 Million
-354,661 Reduced 36.13%
627,094 $21.9 Million
Q4 2022

Feb 13, 2023
SELL
$33.21 - $62.69 $11.8 Million - $22.2 Million
-354,661 Reduced 36.13%
627,094 $21.9 Million
Q3 2022

May 14, 2024
BUY
$53.92 - $71.7 $7.2 Million - $9.58 Million
133,572 Added 15.75%
981,755 $54.9 Million
Q3 2022

Nov 10, 2022
BUY
$53.92 - $71.7 $7.2 Million - $9.58 Million
133,572 Added 15.75%
981,755 $54.9 Million
Q2 2022

May 14, 2024
BUY
$38.49 - $76.21 $910,519 - $1.8 Million
23,656 Added 2.87%
848,183 $43.9 Million
Q2 2022

Aug 15, 2022
BUY
$38.49 - $76.21 $12.2 Million - $24.2 Million
317,167 Added 59.73%
848,183 $43.9 Million
Q1 2022

May 16, 2022
SELL
$58.27 - $118.99 $26.8 Million - $54.7 Million
-460,075 Reduced 46.42%
531,016 $38.6 Million
Q4 2021

Feb 14, 2022
BUY
$100.76 - $138.36 $2.1 Million - $2.88 Million
20,801 Added 2.14%
991,091 $117 Million
Q3 2021

Nov 10, 2021
BUY
$132.37 - $176.78 $128 Million - $172 Million
970,290 New
970,290 $130 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.02B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email